Stock GUJTERC6 GUJARAT TERCE LABORATORIES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Gujarat Terce Laboratories Limited

Equities

GUJTERC6

INE499G01013

Pharmaceuticals

Market Closed - Bombay S.E.
Other stock markets
 03:30:57 02/07/2024 pm IST 		5-day change 1st Jan Change
46.99 INR +4.31% Intraday chart for Gujarat Terce Laboratories Limited -6.95% +64.94%
29/05 Gujarat Terce Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
29/03 Gujarat Terce Laboratories Limited announced that it expects to receive INR 3.496675 million in funding CI

Valuation

Fiscal Period: März 2018 2019 2020 2021 2022 2023
Capitalization 1 87.56 67.52 46.97 51.65 194 123.6
Enterprise Value (EV) 1 83.92 72.51 72.51 86.15 245.7 176
P/E ratio 32.3 x 15.7 x 17.1 x -2.05 x 22.2 x -7.4 x
Yield - - - - - -
Capitalization / Revenue 0.3 x 0.22 x 0.13 x 0.21 x 0.48 x 0.26 x
EV / Revenue 0.29 x 0.23 x 0.19 x 0.34 x 0.61 x 0.38 x
EV / EBITDA 26 x 14.9 x 10.6 x -2.92 x 22 x -8.15 x
EV / FCF 1.52 x -6 x -3.26 x -10.7 x -7.43 x 84.1 x
FCF Yield 65.7% -16.7% -30.7% -9.39% -13.5% 1.19%
Price to Book 0.84 x 0.62 x 0.42 x 0.67 x 2.27 x 1.8 x
Nbr of stocks (in thousands) 7,420 7,420 7,420 7,420 7,420 7,420
Reference price 2 11.80 9.100 6.330 6.960 26.15 16.66
Announcement Date 21/08/18 13/08/19 29/07/20 11/08/21 01/08/22 01/08/23
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: März 2018 2019 2020 2021 2022 2023
Net sales 1 290.1 310.3 375.4 251.8 401.3 467.8
EBITDA 1 3.232 4.861 6.831 -29.46 11.18 -21.59
EBIT 1 1.38 2.748 4.415 -31.23 8.416 -25.24
Operating Margin 0.48% 0.89% 1.18% -12.4% 2.1% -5.39%
Earnings before Tax (EBT) 1 3.253 3.458 4.359 -25.32 7.466 -28.94
Net income 1 2.708 4.326 2.762 -25.2 8.723 -16.72
Net margin 0.93% 1.39% 0.74% -10.01% 2.17% -3.57%
EPS 2 0.3649 0.5800 0.3700 -3.400 1.176 -2.253
Free Cash Flow 1 55.15 -12.08 -22.27 -8.087 -33.07 2.094
FCF margin 19.01% -3.89% -5.93% -3.21% -8.24% 0.45%
FCF Conversion (EBITDA) 1,706.34% - - - - -
FCF Conversion (Net income) 2,036.49% - - - - -
Dividend per Share - - - - - -
Announcement Date 21/08/18 13/08/19 29/07/20 11/08/21 01/08/22 01/08/23
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: März 2018 2019 2020 2021 2022 2023
Net Debt 1 - 4.99 25.5 34.5 51.6 52.4
Net Cash position 1 3.64 - - - - -
Leverage (Debt/EBITDA) - 1.026 x 3.739 x -1.171 x 4.62 x -2.428 x
Free Cash Flow 1 55.1 -12.1 -22.3 -8.09 -33.1 2.09
ROE (net income / shareholders' equity) 2.65% 4.07% 2.52% -26.8% 10.8% -21.7%
ROA (Net income/ Total Assets) 0.4% 0.89% 1.32% -8.81% 2.14% -5.64%
Assets 1 676.8 488.7 208.6 286.1 408.5 296.3
Book Value Per Share 2 14.00 14.60 15.00 10.30 11.50 9.250
Cash Flow per Share 2 0.9900 0.2500 0.0600 1.730 0.0100 2.740
Capex 1 2.77 3.97 4.81 5.04 21.1 0.63
Capex / Sales 0.96% 1.28% 1.28% 2% 5.27% 0.13%
Announcement Date 21/08/18 13/08/19 29/07/20 11/08/21 01/08/22 01/08/23
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Generic Pharmaceuticals

1st Jan change Capi.
GUJARAT TERCE LABORATORIES LIMITED Stock Gujarat Terce Laboratories Limited
+64.94% 4.01M
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+21.01% 43.7B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+28.80% 23.11B
SANDOZ GROUP AG Stock Sandoz Group AG
+20.07% 15.43B
CIPLA LIMITED Stock Cipla Limited
+19.45% 14.31B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+55.92% 12.87B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-12.32% 6.45B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+13.00% 5.55B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. GUJTERC6 Stock
  4. Financials Gujarat Terce Laboratories Limited